These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 21358753)

  • 1. Presence of tumoural C-reactive protein correlates with progressive prostate cancer.
    Elsberger B; Lankston L; McMillan DC; Underwood MA; Edwards J
    Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):122-8. PubMed ID: 21358753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of hypoxia inducible factor-1 alpha in matched hormone naive and castrate resistant prostate cancer specimens.
    Elsberger B; Lankston L; Orange C; Underwood MA; Edwards J
    Cancer Biomark; 2010-2011; 8(1):1-9. PubMed ID: 21896985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
    Lehrer S; Diamond EJ; Mamkine B; Droller MJ; Stone NN; Stock RG
    BJU Int; 2005 May; 95(7):961-2. PubMed ID: 15839913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer.
    McCall P; Catlow J; McArdle PA; McMillan DC; Edwards J
    Cancer Biomark; 2011-2012; 10(2):91-9. PubMed ID: 22430136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
    Edwards J; Traynor P; Munro AF; Pirret CF; Dunne B; Bartlett JM
    Clin Cancer Res; 2006 Jan; 12(1):123-30. PubMed ID: 16397033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up.
    McArdle PA; Qayyum T; McMillan DC
    Urol Int; 2010; 84(4):430-5. PubMed ID: 20395655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
    Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer.
    Koike Y; Miki C; Okugawa Y; Yokoe T; Toiyama Y; Tanaka K; Inoue Y; Kusunoki M
    J Surg Oncol; 2008 Dec; 98(7):540-4. PubMed ID: 18937231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
    Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
    Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
    Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer.
    Castilla C; Congregado B; Conde JM; Medina R; Torrubia FJ; Japón MA; Sáez C
    Urology; 2010 Oct; 76(4):1017.e1-6. PubMed ID: 20708221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study.
    Siemes C; Visser LE; Coebergh JW; Splinter TA; Witteman JC; Uitterlinden AG; Hofman A; Pols HA; Stricker BH
    J Clin Oncol; 2006 Nov; 24(33):5216-22. PubMed ID: 17114654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma.
    Shimada H; Nabeya Y; Okazumi S; Matsubara H; Shiratori T; Aoki T; Sugaya M; Miyazawa Y; Hayashi H; Miyazaki S; Ochiai T
    J Surg Oncol; 2003 Aug; 83(4):248-52. PubMed ID: 12884238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bad expression influences time to androgen escape in prostate cancer.
    Teo K; Gemmell L; Mukherjee R; Traynor P; Edwards J
    BJU Int; 2007 Sep; 100(3):691-6. PubMed ID: 17542986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease.
    Wieland A; Kerbl R; Berghold A; Schwinger W; Mann G; Urban C
    Med Pediatr Oncol; 2003 Jul; 41(1):21-5. PubMed ID: 12764738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer.
    Kato T; Suzuki H; Komiya A; Imamoto T; Naya Y; Tobe T; Ichikawa T
    Int J Urol; 2006 Jul; 13(7):915-9. PubMed ID: 16882055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T; Kinjo M; Nutahara K; Higashihara E
    Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers.
    Krajewska M; Turner BC; Shabaik A; Krajewski S; Reed JC
    Prostate; 2006 Jun; 66(8):801-10. PubMed ID: 16482527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.